Stockreport

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

ALX Oncology Holdings Inc.  (ALXO) 
PDF – Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with HER2-posit [Read more]